PRIMARY FOCAL SEGMENTAL GLOMERULOSCLEROSIS
Clinical trials for PRIMARY FOCAL SEGMENTAL GLOMERULOSCLEROSIS explained in plain language.
Never miss a new study
Get alerted when new PRIMARY FOCAL SEGMENTAL GLOMERULOSCLEROSIS trials appear
Sign up with your email to follow new studies for PRIMARY FOCAL SEGMENTAL GLOMERULOSCLEROSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for FSGS? obinutuzumab trial targets tough cases
Disease control CompletedThis phase 2 trial tested the drug obinutuzumab in 20 adults with a kidney disease called primary FSGS. The participants had not responded well to or could not take standard treatments like steroids. The goal was to see if obinutuzumab could reduce protein leakage in the urine, a…
Matched conditions: PRIMARY FOCAL SEGMENTAL GLOMERULOSCLEROSIS
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New kidney drug shows promise in FSGS trial
Disease control CompletedThis Phase 3 trial tested whether sparsentan, a drug that blocks two pathways involved in kidney damage, can better protect kidney function than the standard treatment irbesartan in people with focal segmental glomerulosclerosis (FSGS). The study enrolled 371 adults and children …
Matched conditions: PRIMARY FOCAL SEGMENTAL GLOMERULOSCLEROSIS
Phase: PHASE3 • Sponsor: Travere Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC